Representative intensity and FLIM images acquired simultaneously in the cyan (480/30 nm) and in the orange (579/34 nm) channels in U2OS cells expressing either mTFP1 (left column) or LSSmOrange, (middle column) or both (right column) using a 440nm single wavelength excitation and dual color FLIM system. mTFP1 and LSSmOrange fluorescence lifetimes were recovered separately in the cyan and the orange channel, respectively. Due to the large emission spectrum of mTFP1, spectral bleed-through can be seen in the orange channel. Note that mTFP1 intensity levels were not sufficient for mTFP1 fluorescence lifetime determination in the orange channel. Average fluorescence lifetimes: Alone,  mTFP1 =2.62±0.03ns (n=28),  LSSmOrange =2.76±0.03ns (n=34); Co-expressed,  mTFP1 =2.62±0.03ns (n=23),  LSSmOrange =2.76±0.04ns (n=23). Fluorescence lifetimes were calculated as a mean±SD. (n) indicates number of cells from at least 3 independent experiments. Scale bar = 10 µm.
Supplementary Figure 2: EYFP spectral bleed-through contributes to LSSmOrangemKate2 fluorescence lifetime heterogeneity.
Representative fluorescence intensity and lifetime images acquired using the dual color FLIM system in U2OS cells expressing mTFP1-YFP and LSSmOrange-mKate2. From left to right: intensity ratios are I cyan /I orange = 0.35 (left) and 1.25 (right) mean lifetimes are cyan =2,02ns for both and  orange =2,47ns (left) and2,82ns (right). Note the difference in mTFP1-EYFP fluorescence intensities levels in the cyan channel in presence of LSSmOrannge-mKate2 correlated with the measurement of a higher LSSmOrange fluorescence lifetime in the orange channel. Scale bar = 10 µm.
Supplementary Figure 3:
ShadowG is an effective FRET acceptor for mTFP1 minimizing its spectral bleed-through in the orange channel. Representative fluorescence intensity and lifetime images of U2OS cells expressing mTFP1, mTFP1-YFP, mTFP1-sREACh and mTFP1-ShadowG alone acquired on dual color FLIM system. Average fluorescence lifetimes from left to right; Cyan channel:  mTFP1 =2.62±0.03ns (n=28),  mTFP1-EYFP =2.02±0.04ns (n=15),  mTFP1-sREACh =2.05±0.07ns (n=29), and  mTFP1-ShadowG =2.14±0.05ns (n=21). Orange channel:  mTFP1-EYFP =2.95±0.04ns (n=10),  mTFP1-sREACh = 1.83±.10ns (n=3) corresponding to the EYFP and sREACh fluorescence lifetime contributions. Note that no fluorescence lifetime was recovered for mTFP1-ShadowG and mTFP1, as already seen in figure S1 . Also, for similar mTFP1 fluorescence intensity levels in all conditions (top row), spectral bleed-through was higher in mTFP1-YFP, mTFP1-sREACh conditions while mTFP1-ShadowG was identical to mTFP1 alone. Fluorescence lifetimes were calculated as a mean±SD. (n) indicates number of cells from at least 3 independent experiments. Scale bar = 10 µm. Graphs represent the mean LSSmOrange (orange curve) and EKAR dual (blue curve) ΔLifetime along time (60min) during: (A) baseline followed by DMSO treatment (mean ΔLifetime of -8±2ps for LSSmOrange and -8±2ps for EKAR dual over 60min) (n=10) and (B) baseline (mean ΔLifetime of -3±2ps for LSSmOrange and -2±2ps for EKAR dual over 10min) upon activation by EGF (mean ΔLifetime of -10±1ps for LSSmOrange and -39±2ps for EKAR dual over 30min) and U0126 treatment (mean ΔLifetime of -1±3ps for LSSmOrange and -25±4ps for EKAR dual over 20min) phases (n=23). Graphs represent the mean LSSmOrange-mKate2 (orange curve) and EKAR dual (blue curve) ΔLifetime along time (60min) during: (C) baseline followed by DMSO treatment (mean ΔLifetime of -8±2ps for LSSmOrange and 1±2ps for EKAR dual over 60min) (n=9) and (D) baseline (mean ΔLifetime of 0±2ps for LSSmOrange-mKate2 and EKAR dual over 10min) upon activation by EGF (mean ΔLifetime of -12±1ps for LSSmOrange-mKate2 and -32±1ps for EKAR dual over 30min) and U0126 treatment (mean ΔLifetime of -13±2ps for LSSmOrange-mKate2 and -6±2ps for EKAR dual over 20min) phase (n=26). Cells were serum-starved for 12h with 0.1% serum containing medium and then stimulated with DMSO as a control (1/1000), Fsk (12,5 µM) and EGF (100ng/mL) for 10 min. Cellular lysates were analyzed by immunoblot with antibodies rat anti-TUBA1A clone YL1/2 (1/5000, EMD Millipore, MAB1864), mouse anti-MAP Kinase, activated (1/1000, Sigma Aldric,h M8159) and 1/5000 dilution of horseraldish peroxidase-conjugated anti-mouse or anti-rat antibodies for 1h (Jackson ImmunoResearch Laboratories, 315-035-045 and Bethyl Laboratories, A110-105P).
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